3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Endocrine
2
CNS
2
Genitourinary
1
Conditions
von Hippel-Lindau Disease
2
Pheochromocytoma
2
Paraganglioma
2
Carcinoma, Renal Cell
2
Neuroectodermal Tumors, Primitive
1
Neoplasm Metastasis
1
Kidney Neoplasms
1
Hemangioblastoma
1
Glioblastoma
1
Adenoma, Islet Cell
1
Interventions
3-Iodobenzylguanidine
8
lutetium Lu 177 dotatate
6
gallium Ga 68 dotatate
5
Temozolomide
4
Specimen Handling
4
Magnetic Resonance Spectroscopy
4
anlotinib
3
Everolimus
3
olaparib
2
cabozantinib
2
belzutifan
2
Sunitinib
2
Phenoxybenzamine
2
Nivolumab
2
Fluorodeoxyglucose F18
2
Biopsy
2
Axitinib
2
3-fluorobenzylguanidine
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
vandetanib
1
talazoparib
1
spartalizumab
1
pembrolizumab
1
pazopanib
1
lanreotide
1
guadecitabine
1
fluorodopa F 18
1
fludarabine phosphate
1
copper dotatate CU-64
1
cixutumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Paraganglioma
×
belzutifan
×
CNS
×
Clear all
NCT04924075
2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
322 enrolled
1 FDA
NCT07167329
2025-09-11
BELIEVE-VHL
AC Camargo Cancer Center
Phase 2
Recruiting
100 enrolled